Loading organizations...
Edgewood Oncology is a clinical-stage biotechnology company based in Brookline, Massachusetts, that develops novel precision medicine therapeutics targeting hematologic malignancies and genetically defined solid tumors. The organization's primary clinical asset, BTX-A51, is currently being advanced as a specialized treatment for patients suffering from acute myeloid leukemia and specific forms of breast cancer. Operating with an estimated headcount of two to ten employees, the enterprise recently emerged from stealth mode after successfully securing $20 million in Series A financing to support its ongoing clinical trials and research operations. This initial funding round was led by venture capital firm Alta Partners, and the corporate board features prominent industry figures associated with organizations such as MBrace Therapeutics and Hebrew University. Edgewood Oncology was officially founded in 2023 by chief executive officer and scientific researcher David N. Cook.
Edgewood Oncology has raised $20.0M across 1 funding round.
Edgewood Oncology has raised $20.0M in total across 1 funding round.
Edgewood Oncology has raised $20.0M in total across 1 funding round.
Edgewood Oncology's investors include Alta Partners, 5AM Ventures, Kiersten Stead.
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a novel small molecule multi-kinase inhibitor that synergistically targets master regulators of cancer to induce programmed cell death.[1][2] It serves patients with hematologic malignancies like relapsed/refractory acute myeloid leukemia (R/R AML) and high-risk myelodysplastic syndrome (HR-MDS), as well as genetically-defined solid tumors such as GATA3-mutant breast cancer, addressing unmet needs in these hard-to-treat populations with promising Phase 1 safety and efficacy data.[1][2][5] The company emerged from stealth in March 2024 with $20 million in Series A financing from Alta Partners to advance Phase 2 trials, adopting a virtual model for efficient development.[2]
Edgewood Oncology was formed in 2024 to advance BTX-A51 based on its synergistic mechanism, favorable safety profile, and anti-tumor activity observed in Phase 1 trials for AML and solid tumors.[2] Led by CEO David N. Cook, Ph.D., a biotech veteran, the leadership team comprises seasoned executives focused on precision medicine for patients lacking effective options.[2] The company launched from stealth on March 25, 2024, securing $20 million in Series A funding from Alta Partners to initiate Phase 2 studies in R/R AML (combined with azacitidine) and GATA3-mutant breast cancer in Q2 2024.[2]
Edgewood rides the wave of precision oncology, targeting genetically-defined cancers amid rising demand for therapies beyond standard chemo in AML (high relapse rates) and GATA3-mutant breast cancer (poor prognosis).[1][5] Timing aligns with post-2024 biotech funding recovery and advances in multi-kinase inhibitors, leveraging Phase 1 data from prior studies to fast-track Phase 2.[2] Market forces like unmet needs in R/R hematologic malignancies (limited options post-venetoclax/azacitidine) and breast cancer resistance favor its profile; Edgewood influences the ecosystem by validating BTX-A51's potential in combinations, potentially expanding to broader solid tumors.[2][5]
Edgewood's near-term catalysts include Phase 2a data readouts in R/R AML (with azacitidine) and GATA3-mutant breast cancer, building on Phase 1 CRis and safety—key to de-risking and attracting follow-on investment.[2][5] Trends like AI-driven patient stratification and combo therapies will shape progress, positioning BTX-A51 for partnerships or expansion if efficacy holds. Influence may grow via proof-of-concept in precision subsets, delivering on its founding promise for unmet needs in oncology.[1][2]
Edgewood Oncology has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in March 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2024 | $20M Series A | Alta Partners | 5AM Ventures, Kiersten Stead | Announced |
